Multidrug-resistant (MDR) and extensively drug-resistant (XDR) Pseudomonas aeruginosa
isolates are frequent causes of serious nosocomial infections that may compromise the …

ABSTRACT β-Lactamases, the major resistance determinant for β-lactam antibiotics in Gram-
negative bacteria, are ancient enzymes whose origins can be traced back millions of years …

Infections of antibiotic-resistant pathogens pose an ever-increasing threat to mankind. The
investigation of novel approaches for tackling the antimicrobial resistance crisis must be part …

Ceftazidime-avibactam (Zavicefta®) is an intravenously administered combination of the
third-generation cephalosporin ceftazidime and the novel, non-β-lactam β-lactamase …

The spread of resistant bacteria, leading to untreatable infections, is a major public health
threat but the pace of antibiotic discovery to combat these pathogens has slowed down …

There is growing global recognition that the continued emergence of multidrug-resistant
bacteria poses a serious threat to human health. Action plans released by the World Health …

Background. When combined with ceftazidime, the novel non–β-lactam β-lactamase
inhibitor avibactam provides a carbapenem alternative against multidrug-resistant infections …

β‐Lactam antibiotics are the most commonly used antibacterial agents and growing
resistance to these drugs is a concern. Metallo‐β‐lactamases are a diverse set of enzymes …

The growing number of bacterial pathogens that are resistant to numerous antibiotics is a
cause for concern around the globe. There have been no new broad‐spectrum antibiotics …

Avibactam is a β-lactamase inhibitor that is in clinical development, combined with β-lactam
partners, for the treatment of bacterial infections comprising Gram-negative organisms …